CN1395938A - Veterinary oral liquid containing oligofructose - Google Patents
Veterinary oral liquid containing oligofructose Download PDFInfo
- Publication number
- CN1395938A CN1395938A CN 02129544 CN02129544A CN1395938A CN 1395938 A CN1395938 A CN 1395938A CN 02129544 CN02129544 CN 02129544 CN 02129544 A CN02129544 A CN 02129544A CN 1395938 A CN1395938 A CN 1395938A
- Authority
- CN
- China
- Prior art keywords
- oligofructose
- oral liquid
- distilled water
- antibacterials
- auxiliary element
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An oral-applied liquid veterinary medicine containing oligofructose for treating diarrhea of animals is prepared through dissolving the antibacterial medicine and assistant in distilled water and dissolving oligofructose in it. Its advantages are quickly taking its effect, high stability, no toxic by-effect and no recurrence.
Description
The present invention is a kind of prescription and production technology that contains the veterinary oral liquid of oligofructose, relates to animal health product and production field thereof.
Animal enteritis is a kind of important diseases that (comprises house pet) in China's animal farming industry, and this disease not only causes the direct death of animal, and has a strong impact on the normal growth promoter of animal, to the influence of aquaculture economic benefit greatly.
At present, the prophylactico-therapeutic measures of animal enteritis mainly comprises: add means such as antibacterials (comprising many newtype drugs, as apramycin, florfenicol), antibacterials control, the fluid infusion of oral electrolyte multidimensional, employing vaccine immunity in some conventional measures (as insulation, sterilization, nutrition), the daily ration.
Because in animal enteritis clinical treatment, the general single means that only adopt the control cause of disease, ignored symptomatic treatment, effect is often undesirable, forcing the client is just to rotate medicine urgently in medication during less than a course of treatment, final consequence singly is not to have incured loss through delay treatment opportunity, the more important thing is that the people is the superpower bacterial strain that produces anti-multiple medicine.In addition, therapeutic effect is not good, often blindly strengthens the using dosage of medicine easily yet, causes the animal growth of later stage to grow and suppresses.
For this reason, we have invented a kind of new oral liquid, and symptoms such as the diarrhoea that this oral liquid directly causes at animal enteritis, body dehydration and dysbacteriosis are by comprehensive treating both the principal and secondary aspects of a disease principle component design, comprise and kill cause of disease, dysentery relieving, fluid infusion, probiotics multiplicaiton factor, this oral liquid adopts the administration of oral painlessization mode, and the medicine focus of going directly is easy to use, dosage is accurate, inorganization stimulates, and has satisfied clinical requirement, has guaranteed curative effect.
The contained oligofructose (Fructooligosacchride) of this oral liquid is a kind of multiplicaiton factor of animal intestinal probiotics, and molecular formula is: G-F-Fn (n=3-5), wherein G is that glucose, F are that fructose, n are the molecule number.Its structural formula is as follows:
1 (1-β-fructofuranosyl)-sucrose
The oligofructose chemical constitution
Oligofructose is not by animal self intestinal absorption, it is not the harmful intestinal tract bacteria utilization yet, but be acknowledged as the good cultivation effect that has to probioticss such as bacillus bifidus, lactobacillus, Eubacterium in the animal intestinal, therefore utilize the competition between flora can regulate the animal intestinal function, control animal diarrhoea.Probiotics propagation also shows as: suppress the pathogenic microorganism growth, improve the body non-specific immunity, promote vitamin and mineral to absorb, reduce the drainage of harmful substance etc.Therefore oligofructose is a kind of good animal diarrhoea prevention medicine.
But in clinical disease control, because after animal suffered from diarrhoea, the pathogenic microorganism in the intestinal is breeding in a large number, use the oligofructose therapeutic effect very inconsistent this moment, bad during the fashion of performance, therefore should cooperate other drug with the assurance curative effect.
Contain oligofructose, antibacterials, auxiliary element, distilled water in the prescription of this veterinary oral liquid.
Main component consists of in the oral liquid prescription: oligofructose content is that 5-75% (W/V), antibacterials 0.01-20% (W/V), auxiliary element 0.01-30% (W/V), distilled water are an amount of.
Antibacterials described in the oral liquid prescription comprise chloromycetin, as thiamphenicol, Florfenicol; Tetracyclines is as doxycycline; Fluoroquinolones is as norfloxacin, ciprofloxacin, enrofloxacin; Beta-lactam is as amoxicillin, clavulanic acid; Aminoglycoside is as gentamycin, neomycin, peace platenomycin; The lincomycin class is as lincomycin; The polypeptide class is as polymyxin; Sulfanilamide and synergist thereof are as sulfadimidine, sulfanilamide hexakis-methoxy pyrimidine, TMP, DVD; Other synthetic antibacterial drugs as LIJUNJING, furazolidone, also comprise these antimicrobial drug derivants.Described antibacterials can be selected a kind of in the above medicine separately for use, but also two or more mixes and uses.
Auxiliary element described in the oral liquid prescription comprise zinc sulfate, Alumen, bismuth subnitrate, bismuth subcarbonate, dipyrone, sodium salicylate, aminophenazone, atropine sulfate, Semen daturae, scopolamine, potassium chloride, glycyrrhizin, Sai Misong, meticortelone, benzoic acid, tween, sorbic acid.Described auxiliary element can be selected a kind of in the above medicine separately for use, but also two or more mixes and uses.
Distilled water described in the oral liquid prescription also can be selected redistilled water and deionized water for use.
This oral liquid process can be dissolved in an amount of distilled water with antibacterials and auxiliary element earlier, again the oligofructose syrup is added dissolving, makes clarifying oral liquid; Also can be earlier the oligofructose syrup be added dissolved in distilled water, add antibacterials successively again with auxiliary element fully dissolves, clarifying oral liquid is made in filtration.
For further understanding the present invention, describe feature of the present invention with example below, but example does not limit the right protection scope.It only is the part in the right protection scope.
Example 1
Prescription: 100ml content (W/V)
Oligofructose 10 grams
Ciprofloxacin 10 grams
TMP 2 grams
Bismuth subnitrate 0.5 gram
Zinc sulfate 2 grams
Benzoic acid is an amount of
Distilled water adds to 100 milliliters
Production technology: at first that ciprofloxacin 10 gram, TMP 2 grams, bismuth subnitrate 0.5 gram, zinc sulfate 2 grams, benzoic acid is an amount of, add fully dissolving in 70 milliliters of the distilled water successively, gained solution adds the syrup that contains oligofructose 10 grams, continue stirring and dissolving, with distilled water polishing to 100 milliliter, filter, filling bottle promptly gets clarifying oral liquid.
Example 2
Prescription: 100ml content (W/V)
Oligofructose 10 grams
Ciprofloxacin 10 grams
TMP 2 grams
Bismuth subnitrate 0.5 gram
Zinc sulfate 2 grams
Benzoic acid is an amount of
Distilled water adds to 100 milliliters
Production technology: the syrup that at first will contain oligofructose 10 grams, add 70 ml distilled water stirring and dissolving, it is an amount of that gained solution adds ciprofloxacin 10 gram, TMP 2 grams, bismuth subnitrate 0.5 gram, zinc sulfate 2 grams, benzoic acid successively, continue stirring and dissolving, use distilled water polishing to 100 milliliter at last, filter, filling bottle promptly gets clarifying oral liquid.
Example 3
Prescription: 100ml content (W/V)
Oligofructose 10 grams
Ciprofloxacin 10 grams
Bismuth subnitrate 0.5 gram
Zinc sulfate 2 grams
Benzoic acid is an amount of
Distilled water adds to 100 milliliters
Production technology: at first that ciprofloxacin 10 gram, bismuth subnitrate 0.5 gram, zinc sulfate 2 grams, benzoic acid is an amount of, add fully dissolving in 70 milliliters of the distilled water successively, gained solution adds the syrup that contains oligofructose 10 grams, continue stirring and dissolving, with distilled water polishing to 100 milliliter, filter, filling bottle promptly gets clarifying oral liquid.
Example 4
Prescription: 100ml content (W/V)
Oligofructose 10 grams
Ciprofloxacin 10 grams
Bismuth subnitrate 0.5 gram
Zinc sulfate 2 grams
Benzoic acid is an amount of
Distilled water adds to 100 milliliters
Production technology: the syrup that at first will contain oligofructose 10 grams, add 70 ml distilled water stirring and dissolving, it is an amount of that gained solution adds ciprofloxacin 10 gram, bismuth subnitrate 0.5 gram, zinc sulfate 2 grams, benzoic acid successively, continue stirring and dissolving, use distilled water polishing to 100 milliliter at last, filter, filling bottle promptly gets clarifying oral liquid.
Claims (6)
1, a kind of prescription that contains the veterinary oral liquid of oligofructose contains oligofructose, antibacterials, auxiliary element, distilled water.
2, a kind of production technology that contains the veterinary oral liquid of oligofructose is characterized in that: antibacterials and auxiliary element are dissolved in an amount of distilled water, the oligofructose syrup are added fully dissolving again, filter, make clarifying oral liquid.
3, a kind of as the right 1 described prescription that contains the veterinary oral liquid of oligofructose, it is characterized in that: oligofructose content is that 5-70% (W/V), antibacterials 0.01-20% (W/V), auxiliary element 0.01-20% (W/V), distilled water are an amount of.
4, a kind of as the right 1 described prescription that contains the veterinary oral liquid of oligofructose, it is characterized in that: used antibacterials can be selected one or more in peace platenomycin, thiamphenicol, Florfenicol, doxycycline, norfloxacin, ciprofloxacin, enrofloxacin, amoxicillin, gentamycin, neomycin, lincomycin, polymyxin, sulfadimidine, sulfanilamide hexakis-methoxy pyrimidine, TMP, DVD, LIJUNJING, furazolidone and the derivant thereof for use.
5, a kind of as the right 1 described prescription that contains the veterinary oral liquid of oligofructose, it is characterized in that: used auxiliary element can select for use zinc sulfate, Alumen, bismuth subnitrate, bismuth subcarbonate, dipyrone, sodium salicylate, aminophenazone, atropine sulfate, Semen daturae, scopolamine, potassium chloride, glycyrrhizin, one or more of Sai Misong, meticortelone, benzoic acid, tween, sorbic acid.
6, a kind of as the right 2 described production technologies that contain the veterinary oral liquid of oligofructose, it is characterized in that: earlier the oligofructose syrup is added dissolved in distilled water, add antibacterials successively again with auxiliary element fully dissolves, clarifying oral liquid is made in filtration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02129544 CN1395938A (en) | 2002-09-03 | 2002-09-03 | Veterinary oral liquid containing oligofructose |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02129544 CN1395938A (en) | 2002-09-03 | 2002-09-03 | Veterinary oral liquid containing oligofructose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1395938A true CN1395938A (en) | 2003-02-12 |
Family
ID=4746286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02129544 Pending CN1395938A (en) | 2002-09-03 | 2002-09-03 | Veterinary oral liquid containing oligofructose |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1395938A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101060861A (en) * | 2004-09-16 | 2007-10-24 | 高露洁-棕榄公司 | Method and composition for preventing or treating diarrhea |
-
2002
- 2002-09-03 CN CN 02129544 patent/CN1395938A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9028861B2 (en) | 2003-03-12 | 2015-05-12 | Hill's Pet Nutrition, Inc. | Method and composition to reduce diarrhea in a companion animal |
| CN101060861A (en) * | 2004-09-16 | 2007-10-24 | 高露洁-棕榄公司 | Method and composition for preventing or treating diarrhea |
| US8563029B2 (en) | 2004-09-16 | 2013-10-22 | Hill's Pet Nutrition, Inc. | Exopolysaccharide containing food |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| CN1903171A (en) | Nanometer silver type external use antibiotic gel for female external use and its prepn. method | |
| CN1903289A (en) | Gel for treating hemorrhoidal anus and rectum diseases, and its prepn. method | |
| Norrby et al. | Interaction between cephaloridine and furosemide in man | |
| CN1137899A (en) | Gargle for aphtha | |
| CN1830440A (en) | Metronidazule injection and its preparation method and use | |
| CN1533776A (en) | Application of N-acetly glucosamine in the preparation of medicine for treating local injury and full body syndrome due to virus or bacterial infestation | |
| CN1395938A (en) | Veterinary oral liquid containing oligofructose | |
| CN1990487A (en) | Berberine ion pair compound, preparing method and drug containing same | |
| CN1086289C (en) | Medicine for treating diabetes and nephrosis containing rheinic acid | |
| CN102600304A (en) | Nanoemulsion composition for treating mycoplasma pneumonia of livestock and preparation method of nanoemulsion composition | |
| CN1754539A (en) | Tetrodotoxin oil phase formulation preparation method | |
| CN102580093B (en) | Injection for preventing piglet diseases and preparation method thereof | |
| CN1096446A (en) | Compound flavescent sophora root injection for animals | |
| EP3733176B1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof | |
| EP2606885B1 (en) | Medicinal preparation "renessans" having an antibacterial, anti-ulcerous and immuno-modulating action | |
| CN107875154B (en) | Composition containing piperacillin, pharmaceutical preparation and application thereof | |
| CN1546020A (en) | Vaginal effervescence tablet of secnidazole and its preparation | |
| RU2571819C2 (en) | Immunometabolic formulation with antimicrobial activity | |
| CN1203862C (en) | Compound glucose injection with clindamycin and metronidazole | |
| CN1432357A (en) | Fever allaying prepn containing xylitol | |
| CN1095269A (en) | Broad-spectrum antibiotic for animal | |
| CN106822247A (en) | Amikacin sulfate injection and preparation method thereof | |
| CN116570557A (en) | Prescription of litsea cubeba oil oral liquid as veterinary medicine and its preparing process | |
| JPS62246517A (en) | Synergistic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |